IL-4 and IL-13 were upregulated in ILC2s cells, particularly in PD-1high ILC2s in NSCLC patients, and boosted M2-like macrophage polarization, warranting clinical trials of Dupilumab in NSCLC patients in the future. Here, IL13 is linked to non-small cell lung carcinoma.